A Phase II Trial of Docetaxel and Ifosfamide for Patients with Platinum-Resistant or Refractory Non-Small Cell Lung Cancer in a Salvage Setting

Purpose: W hen used in the second-line setting, singleagent chemotherapy has produced response rates of more than 10% or median survival times greater than 4 months. W e studied the safety and efficacy of using second-line single docetaxel (75 mg/m 2 ) for advanced NSCLC patients who were previously treated with platinum-based chemotherapy in Korea.Materials and Methods: Thirty-three patients with advanced NSCLC received chemotherapy from May 2002 to January 2005. W e retrospectively reviewed the charts of these patients. The patients received 75 mg/m 2 of doxetaxel on day 1 and this was repeated at 3-week intervals.Results: The median age was 63 years (range: 42～77 years); 16 patients had adenocarcinoma and 8 patients had squamous cell carcinoma. The median number of cycles was 4 (range: 1～7 cycles). Of the 33 patients, 6 patients had partial responses, 13 patients had stable disease and 14 patients had progressive disease. The response rate was 18.2% . The median overall survival was 11 months (range: 7～15 months), and the median progression free survival was 5 months (range: 3～7 months). The median response duration was 5 months (range: 4～9 months). A total of 137 cycles were evaluated for toxicity. W e observed grade 3 or 4 neutropenia in 79 cycles (57.6% ), grade 3 or 4 leukopenia in 46 cycles (33.6% ), and grade 3 febrile neutropenia in 2 cycles (1.5% ). The median nadir day was day 9 (range: day 5～ 19), and the median number of G-CSF injections was 2 (range: 0～6). The most common non-hematologic toxicities were myalgia/arthralgia and neurotoxicity, but any grade 3 or 4 non-hematologic toxicity was not observed. The major toxicity of this therapy was neutropenia. The absolute neutrophil count decreased relatively rapidly, but neutropenic fever or related infection was rare. There were no treatment-related deaths.Conclusion: These results revealed a satisfactory response rate (18.2% ) with using docetaxel as the secondline chemotherapy for NSCLC. The second-line docetaxel was an active and well-tolerated regimen in patients with advanced NSCLC pretreated with platinum-based chemotherapy. (Cancer Res Treat. 2005;37:339-343)

show abstract

The Safety and Efficacy of Second-line Single Docetaxel (75 mg/m2) Therapy in Advanced Non-Small Cell Lung Cancer Patients who were Previously Treated with Platinum-based Chemotherapy

Shim

Kim

Song

et al. 2005

Cancer Res Treat

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A Phase II Trial of Docetaxel and Ifosfamide for Patients with Platinum-Resistant or Refractory Non-Small Cell Lung Cancer in a Salvage Setting

Abstract: Purpose:We conducted a phase II study of docetaxel and ifosfamide chemotherapy for patients with platinum-resistant or refractory non-small-cell lung cancer (NSCLC) to evaluate the response and toxicity profiles as a salvage treatment.

Cited by 1 publication

References 21 publications

The Safety and Efficacy of Second-line Single Docetaxel (75 mg/m2) Therapy in Advanced Non-Small Cell Lung Cancer Patients who were Previously Treated with Platinum-based Chemotherapy

The Safety and Efficacy of Second-line Single Docetaxel (75 mg/m2) Therapy in Advanced Non-Small Cell Lung Cancer Patients who were Previously Treated with Platinum-based Chemotherapy

Contact Info

Product

Resources

About